Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Gilead Sciences |
---|---|
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00326157 |
This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome® loading dose regimen, in a weekly administration schedule during the initial phase of allogeneic stem-cell transplant and in case of occurrence of graft versus host disease (GvHD), which are both high risk periods as far as severe fungal infection development is concerned.
Condition | Intervention | Phase |
---|---|---|
Fungus Diseases |
Drug: AmBisome |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Pilot Study on Safety of Administration of 3mg/kg/Day Three Times a Week Until Day 22 (21 Days After Transplantation Day) and 7 mg/kg Weekly From Day 29 to the End of Treatment (Day 50-8th Week) of AmBisome® in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem-Cell Transplantation |
Estimated Enrollment: | 40 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
AmBisome® will be administered for a duration of 8 weeks
|
Drug: AmBisome
3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
|
This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome® loading dose regimen, in a weekly administration schedule during the initial phase of allogeneic stem-cell transplant and in case of occurrence of GvHD, which are both high risk periods as far as severe fungal infection development is concerned.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Loredana Balzano | +39 02 43920239 | RosariaLoredana.Balzano@gilead.com |
Italy | |
Gilead Sciences | Recruiting |
Milan, Italy, 20146 |
Study Director: | Pier Luigi Carriero, MD | Gilead Sciences |
Responsible Party: | Gilead Sciences ( Pier Luigi Carriero ) |
Study ID Numbers: | GS-IT-131-0151 |
Study First Received: | May 10, 2006 |
Last Updated: | November 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00326157 |
Health Authority: | Italy: The Italian Medicines Agency |
antifungal primary prophylaxis treatment allogeneic stem-cell transplantation antifungal primary prophylaxis treatment of high risk patients undergoing allogeneic stem-cell transplantation |
Abelcet Amphotericin B Mycoses Clotrimazole |
Miconazole Tioconazole Liposomal amphotericin B |
Anti-Infective Agents, Local Anti-Bacterial Agents Anti-Infective Agents Antiparasitic Agents Antiprotozoal Agents |
Antifungal Agents Therapeutic Uses Antibiotics, Antifungal Amebicides Pharmacologic Actions |